View Future GrowthThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsAltitude Acquisition 과거 순이익 실적과거 기준 점검 0/6Altitude Acquisition의 연간 평균 수익은 2.3%였으며, Capital Markets 산업의 수익은 연간 6.1% 증가했습니다.핵심 정보2.27%순이익 성장률-206.07%주당순이익(EPS) 성장률Capital Markets 산업 성장률10.26%매출 성장률n/a자기자본이익률n/a순이익률n/a최근 순이익 업데이트30 Sep 2023최근 과거 실적 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • Apr 24Altitude Acquisition Corp. Files Form 15Altitude Acquisition Corp. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its Units, each consisting of one share of Class A common stock and one-half of one redeemable warrant, Class A common stock, par value $0.0001, Redeemable warrants, each warrant exercisable for one share of Class A common stock, each at an excise price of $11.50 per share under the Securities Exchange Act of 1934, as amended.공시 • Mar 14+ 1 more updateAltitude Acquisition Corp.(NasdaqCM:ALTU) dropped from NASDAQ Composite IndexAltitude Acquisition Corp. has been removed from NASDAQ Composite Index .공시 • Nov 15Altitude Acquisition Corp. announced delayed 10-Q filingOn 11/14/2023, Altitude Acquisition Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.Board Change • Dec 31High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. No experienced directors. No highly experienced directors. Founder, President, CEO & Director Gary Teplis is the most experienced director on the board, commencing their role in 2020. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.공시 • Oct 05Altitude Acquisition in Talks to Merge with Medical Device ManufacturerAltitude Acquisition Corp. (NasdaqCM:ALTU), a publicly traded special purpose acquisition company, said it has entered into negotiations to merge with a "leading global medical device manufacturer in a deal that pegs the enterprise value of the company at approximately $480 million." The proposed transaction calls for the combined company to have at least $20 million in net cash at time of closing. The target seeks additional expansion in the U.S., globally and in new jurisdictions around the world, Altitude said in a statement. Altitude anticipates entering into a letter of intent on or around October 31 and a definitive merger agreement as soon as practicable thereafter. "We believe the target is a market leader in its field and a business combination would represent a tremendous opportunity for us and our shareholders," said Gary Teplis, Chief Executive Officer of Altitude. "I would also like to remind our stockholders that Altitude is seeking stockholder approval of an extension of time to complete our initial business combination, from October 11, 2022, to April 11, 2023 (the "Extension")".공시 • Sep 14Altitude Acquisition Corp. Announces Executive ChangesOn September 7, 2022, Gavin Isaacs notified Altitude Acquisition Corp. of his decision to resign from his position as Chairman of the board of directors of the Company and from the audit committee of the Board effective immediately.On September 9, 2022, Thomas Breitling notified the Company of his decision to resign from his position as Vice Chairman of the Board and from the compensation committee of the Board effective immediately. In connection with the resignations of Mr. Isaacs and Mr. Breitling, on September 13, 2022, the Board appointed Dr. Warren Hosseinion to serve as a Class III director on the Board, Chairman of the Board, and as a member of the Audit Committee and Compensation Committee, effective immediately. Dr. Hosseinion, 46, is a co-founder of Apollo Medical Holdings Inc., has been a member of its board of directors since July 2008, and served as its Chief Executive Officer from July 2008 to December 2017 and Co-Chief Executive Officer from December 2017 to March 2019. Dr. Hosseinion was Chairman of the board of directors of Clinigence Holdings Inc. from April 2019 to March 2022, Chief Executive Officer of Clinigence Holdings Inc. from March 2021 to March 2022, and following a business combination with Nutex Health Inc. he continues to be a director and President of Nutex Health Inc. from March 2022 to present. In 2001, Dr. Hosseinion co-founded ApolloMed. Dr. Hosseinion received his B.S. in Biology from the University of San Francisco, his M.S. in physiology and biophysics from the Georgetown University Graduate School of Arts and Sciences, his medical degree from the Georgetown University School of Medicine, and completed his residency in internal medicine from the Los Angeles County-University of Southern California Medical Center.공시 • Aug 23Altitude Acquisition Corp. Announces Resignation of Kevin Schubert as Chief Operating Officer, Effective August 18, 2022On August 18, 2022, Kevin Schubert notified Altitude Acquisition Corp. of his decision to resign from his position as Chief Operating Officer, effective August 18, 2022. Mr. Schubert’s decision to resign is not related to any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.공시 • Aug 17Altitude Acquisition Corp. announced delayed 10-Q filingOn 08/16/2022, Altitude Acquisition Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공시 • Aug 26Getaround Reportedly in Talks to Go Public Through A Merger with Altitude AcquisitionGetaround is in talks to go public through a merger with special purpose acquisition company (SPAC) Altitude Acquisition Corp. (NasdaqCM:ALTU), people familiar with the matter said. The company has confidentially sought investors to participate in the deal through a private placement in public equity, or PIPE, at a valuation of around $1.7 billion, one of the sources said. The sources cautioned that terms could change and said there was no certainty of a deal. They asked not to be identified because the negotiations are not public. Altitude Acquisition Corp. declined to comment. Getaround did not immediately respond to requests for comment.공시 • May 18Altitude Acquisition Corp. announced delayed 10-Q filingOn 05/17/2021, Altitude Acquisition Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공시 • Feb 19Aerion Reportedly in Talks to Go Public Through A Merger with Altitude AcquisitionAerion Corporation is in talks to go public through a merger with Altitude Acquisition Corp. (NasdaqCM:ALTU), according to people with knowledge of the matter. The companies are discussing a deal that would value the combined firm at up to $3 billion, said the people, who asked to not be identified because the matter isn’t public. A deal could be announced as soon as in February 2021, the people said. The talks could still fall apart and end without an agreement, they said. A spokesperson for Aerion declined to comment. A representative for Altitude Acquisition didn’t immediately respond to a request for comment.매출 및 비용 세부 내역Altitude Acquisition가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이NasdaqCM:ALTU 매출, 비용 및 순이익 (USD Millions)날짜매출순이익일반관리비연구개발비30 Sep 230-45030 Jun 230-24031 Mar 230-14031 Dec 22093030 Sep 220133030 Jun 220118031 Mar 220306031 Dec 2101560양질의 수익: ALTU 은(는) 현재 수익성이 없습니다.이익 마진 증가: ALTU는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: 지난 5년 동안 ALTU의 연간 수익 성장률이 양(+)이었는지 판단하기에 데이터가 부족합니다.성장 가속화: 현재 수익성이 없어 지난 1년간 ALTU의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: ALTU은 수익성이 없어 지난 해 수익 성장률을 Capital Markets 업계(39.3%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: ALTU의 부채가 자산을 초과하여 자본 수익률을 계산하기 어렵습니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YDiversified-financials 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2024/03/13 15:42종가2024/03/13 00:00수익2023/09/30연간 수익2022/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Altitude Acquisition Corp.는 0명의 분석가가 다루고 있습니다. 이 중 명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
공시 • Apr 24Altitude Acquisition Corp. Files Form 15Altitude Acquisition Corp. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its Units, each consisting of one share of Class A common stock and one-half of one redeemable warrant, Class A common stock, par value $0.0001, Redeemable warrants, each warrant exercisable for one share of Class A common stock, each at an excise price of $11.50 per share under the Securities Exchange Act of 1934, as amended.
공시 • Mar 14+ 1 more updateAltitude Acquisition Corp.(NasdaqCM:ALTU) dropped from NASDAQ Composite IndexAltitude Acquisition Corp. has been removed from NASDAQ Composite Index .
공시 • Nov 15Altitude Acquisition Corp. announced delayed 10-Q filingOn 11/14/2023, Altitude Acquisition Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
Board Change • Dec 31High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. No experienced directors. No highly experienced directors. Founder, President, CEO & Director Gary Teplis is the most experienced director on the board, commencing their role in 2020. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.
공시 • Oct 05Altitude Acquisition in Talks to Merge with Medical Device ManufacturerAltitude Acquisition Corp. (NasdaqCM:ALTU), a publicly traded special purpose acquisition company, said it has entered into negotiations to merge with a "leading global medical device manufacturer in a deal that pegs the enterprise value of the company at approximately $480 million." The proposed transaction calls for the combined company to have at least $20 million in net cash at time of closing. The target seeks additional expansion in the U.S., globally and in new jurisdictions around the world, Altitude said in a statement. Altitude anticipates entering into a letter of intent on or around October 31 and a definitive merger agreement as soon as practicable thereafter. "We believe the target is a market leader in its field and a business combination would represent a tremendous opportunity for us and our shareholders," said Gary Teplis, Chief Executive Officer of Altitude. "I would also like to remind our stockholders that Altitude is seeking stockholder approval of an extension of time to complete our initial business combination, from October 11, 2022, to April 11, 2023 (the "Extension")".
공시 • Sep 14Altitude Acquisition Corp. Announces Executive ChangesOn September 7, 2022, Gavin Isaacs notified Altitude Acquisition Corp. of his decision to resign from his position as Chairman of the board of directors of the Company and from the audit committee of the Board effective immediately.On September 9, 2022, Thomas Breitling notified the Company of his decision to resign from his position as Vice Chairman of the Board and from the compensation committee of the Board effective immediately. In connection with the resignations of Mr. Isaacs and Mr. Breitling, on September 13, 2022, the Board appointed Dr. Warren Hosseinion to serve as a Class III director on the Board, Chairman of the Board, and as a member of the Audit Committee and Compensation Committee, effective immediately. Dr. Hosseinion, 46, is a co-founder of Apollo Medical Holdings Inc., has been a member of its board of directors since July 2008, and served as its Chief Executive Officer from July 2008 to December 2017 and Co-Chief Executive Officer from December 2017 to March 2019. Dr. Hosseinion was Chairman of the board of directors of Clinigence Holdings Inc. from April 2019 to March 2022, Chief Executive Officer of Clinigence Holdings Inc. from March 2021 to March 2022, and following a business combination with Nutex Health Inc. he continues to be a director and President of Nutex Health Inc. from March 2022 to present. In 2001, Dr. Hosseinion co-founded ApolloMed. Dr. Hosseinion received his B.S. in Biology from the University of San Francisco, his M.S. in physiology and biophysics from the Georgetown University Graduate School of Arts and Sciences, his medical degree from the Georgetown University School of Medicine, and completed his residency in internal medicine from the Los Angeles County-University of Southern California Medical Center.
공시 • Aug 23Altitude Acquisition Corp. Announces Resignation of Kevin Schubert as Chief Operating Officer, Effective August 18, 2022On August 18, 2022, Kevin Schubert notified Altitude Acquisition Corp. of his decision to resign from his position as Chief Operating Officer, effective August 18, 2022. Mr. Schubert’s decision to resign is not related to any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.
공시 • Aug 17Altitude Acquisition Corp. announced delayed 10-Q filingOn 08/16/2022, Altitude Acquisition Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공시 • Aug 26Getaround Reportedly in Talks to Go Public Through A Merger with Altitude AcquisitionGetaround is in talks to go public through a merger with special purpose acquisition company (SPAC) Altitude Acquisition Corp. (NasdaqCM:ALTU), people familiar with the matter said. The company has confidentially sought investors to participate in the deal through a private placement in public equity, or PIPE, at a valuation of around $1.7 billion, one of the sources said. The sources cautioned that terms could change and said there was no certainty of a deal. They asked not to be identified because the negotiations are not public. Altitude Acquisition Corp. declined to comment. Getaround did not immediately respond to requests for comment.
공시 • May 18Altitude Acquisition Corp. announced delayed 10-Q filingOn 05/17/2021, Altitude Acquisition Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공시 • Feb 19Aerion Reportedly in Talks to Go Public Through A Merger with Altitude AcquisitionAerion Corporation is in talks to go public through a merger with Altitude Acquisition Corp. (NasdaqCM:ALTU), according to people with knowledge of the matter. The companies are discussing a deal that would value the combined firm at up to $3 billion, said the people, who asked to not be identified because the matter isn’t public. A deal could be announced as soon as in February 2021, the people said. The talks could still fall apart and end without an agreement, they said. A spokesperson for Aerion declined to comment. A representative for Altitude Acquisition didn’t immediately respond to a request for comment.